Treatment with 5α-reductase inhibitors improves disease-specific survival following a diagnosis of bladder cancer, suggests a recent study. On the other hand, α-blockers do not appear to improve bladder cancer survival.
The risk of colorectal cancer (CRC) is significantly higher in patients with chronic kidney disease (CKD), regardless of a history of transplant, according to the results of a systematic review and meta-analysis.
Patients with cancer who use complementary medicine in addition to conventional therapies are likely to refuse additional conventional treatments, according to a study from the US. The use of complementary therapies may also be associated with poorer overall survival (OS).
Administering intravesical gemcitabine immediately after tumour resection leads to a significant reduction in the long-term risk of recurrence in patients with suspected low-grade nonmuscle-invasive urothelial cancer, a study has shown.
Host factors, such as tumour (size, complexity) and patient characteristics (comorbidities, advanced age, abnormal body mass index [BMI], chronic kidney disease [CKD], prior abdominal surgery), affect the outcomes of robotic partial nephrectomy (RPN), according to the results of a meta-analysis.
The addition of pertuzumab to trastuzumab and chemotherapy did not significantly affect overall survival (OS) of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric or gastroesophageal junction cancer, according to the JACOB* trial.
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5